This site is intended for
US healthcare professionals only

For Healthcare Professionals

What is PRIALT?

PRIALT® (ziconotide) intrathecal infusion is an analgesic that is administered directly into the spinal fluid via a pump.1,2,3 The Food and Drug Administration (FDA) has approved PRIALT for use in adults with severe chronic pain when other treatments have proven to be ineffective or intolerable.1

PRIALT is a non narcotic pain management option that may be able to relieve severe chronic pain.2,4

How does PRIALT work?

PRIALT binds to the N-type calcium channels located in the dorsal horn of the spinal cord, blocking the release of excitatory neurotransmitters, which leads to antinociception (as seen in animal studies).1

Studies have demonstrated that PRIALT1:

  • Does not bind to opioid receptors, and its pharmacological effects are not blocked by opioid antagonists.
  • Did not potentiate morphine-induced respiratory depression in animal models.
  • Concurrent administration of IT ziconotide and morphine did not prevent the development of morphine tolerance in rats.5

The appropriate PRIALT patient

Determine if PRIALT is a viable treatment option for managing your patient’s severe chronic pain.

Starting a patient on PRIALT

Understand the recommended procedures for introducing your patient to PRIALT and finding the right dose.


  1. PRIALT® (ziconotide) solution, intrathecal infusion [package insert]. Palo Alto, CA; Jazz Pharmaceuticals.
  2. Rauck RL, Wallace MS, Leong MS, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006; 5: 399-402.
  3. McGivern JG. Targeting N-type and T-type calcium channels for the treatment of pain. Drug Discov Today. 2006; 11: 245.
  4. Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Current Medical Chemistry. 2004; 11: 3029-3030.
  5. Saulino M, Kim PS, Shaw E, et al. Practical considerations and patient selection for intrathecal drug delivery in the management of chronic pain. J Pain Res. 2014; 7: 628-631.